-
Arikayce approved in Japan: the first drug to treat nontuberculous mycobacterial lung disease caused by MAC
Time of Update: 2021-04-27
The study was carried out in patients with refractory NTM lung disease caused by MAC, and the results showed that the study reached the primary endpoint: at the 6th month of treatment, compared with a guideline-based multi-drug regimen (MDR), Arikayce once a day Combined treatment with MDR can significantly increase the conversion rate of sputum culture (p<0.
-
Hutchison Pharma enters into an agreement to sell non-core non-prescription drug joint ventures for US$169 million
Time of Update: 2021-04-27
On March 24, Hutchison Medicine announced that it had reached a US$169 million transaction agreement with GL Mountrose Investment Two Limited, which is controlled and managed by Telford Capital.
100% equity of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co.
-
Hengrui Medicine's PD-1 monoclonal antibody anti-cancer new drug submits two more marketing applications
Time of Update: 2021-04-27
First-line treatment for squamous non-small cell lung cancerThis is a randomized, double-blind, phase 3 controlled clinical study named SHR-1210-III-307, which aims to evaluate carrelizumab for injection or placebo combined with paclitaxel and carboplatin for advanced or metastatic The effectiveness and safety of first-line treatment of squamous NSCLC.
-
AstraZeneca announces phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness
Time of Update: 2021-04-27
On March 25, AstraZeneca announced that the main analysis of the Phase 3 clinical trial of the new crown vaccine AZD1222 has obtained high-level positive results. The results confirmed that its effec
-
Accelerated hospital admission after medical insurance? The top three soared 41 new blockbuster drugs such as Hengrui and Baekje PD-1!
Time of Update: 2021-04-27
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
-
Tibet Weixinkang Pharmaceutical Subsidiary Obtained Drug Registration Certificate for Mixed Glycoelectrolyte Injection
Time of Update: 2021-04-27
On March 26, Tibet Weixinkang Pharmaceutical issued an announcement that its wholly-owned subsidiary Baiyi Pharmaceutical received the "Drug Registration Certificate" for mixed glycoelectrolyte injection approved and issued by the State Drug Administration.
-
The State Food and Drug Administration Revises the Instructions for Mouse Nerve Growth Factor for Injection
Time of Update: 2021-04-27
On March 23, the State Food and Drug Administration issued an announcement on the revision of the instructions for mouse nerve growth factor for injection, and decided to revise the instructions for mouse nerve growth factor for injection [adverse reactions], [precautions] and medications for special populations.
-
Guizhou Bailing: Ruikang Hospital received approval for registration of preparations from medical institutions
Time of Update: 2021-04-27
On March 25, Guizhou Bailing announced that the company signed a "Technology Development (Cooperation) Contract" with Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine
-
Zhejiang's drug access "opens the gate", opportunities for many large varieties are coming
Time of Update: 2021-04-27
List of certain commercial insurance: Medical Network News, March 25, Zhejiang Province has been relatively tight on product access cards since the 2014 standard.
List of certain commercial insurance: Medical Network News, March 25, Zhejiang Province has been relatively tight on product access cards since the 2014 standard.
-
The new requirements of the Health Commission affect a large number of secondary hospitals!
Time of Update: 2021-04-27
The "Task" clarified that, in order to improve the mental health service capabilities of medical institutions, 100% psychiatric hospitals in the pilot area have set up mental outpatient clinics, and 40% of general hospitals above the second level open mental (psychological) outpatient clinics.
-
A pharmaceutical company fined 10,000 yuan for producing and selling unqualified pharmaceutical packaging materials
Time of Update: 2021-04-27
The content and basis of administrative punishment:According to the provisions of Article 64 Paragraph 2 of the "Administrative Measures for Packaging Materials and Containers in Direct Contact with Drugs", supervise and process 669,630 sets of oral liquid medicinal high-density polyethylene bottles (batch number: 19081301) produced by your company, and provide you with The company imposed a fine of 10,000 yuan.
-
A wholly-owned subsidiary of Tus Pharmaceuticals obtained the "Drug Production License"
Time of Update: 2021-04-27
The solid comprehensive preparation workshop and comprehensive extraction workshop production line involved in some of the fund-raising projects implemented by the Chinese Medicine Company have passed the on-site inspection of drug GMP compliance by the Hunan Provincial Drug Administration, and completed the modification record of the "Drug Production License".
-
Hebei Province: Strengthening the supervision and inspection of medical expenses and prohibiting large prescriptions
Time of Update: 2021-04-27
Standardize the interactive process of doubtful points—strengthen the effect of agreement clauses and indicator constraints, and include priority use of medical insurance catalog drugs (medical consumables), control of the proportion of self-pay, prohibition of inducing drugs to be purchased out of hospitals, and issuing large prescriptions in violation of regulations, etc.
-
Fosun Pharma's stock price fell on suspension of vaccination of two batches of new crown vaccine! The company responded urgently...
Time of Update: 2021-04-27
On March 16, 2020, Fosun Pharma and the company reached a new crown vaccine research and development cooperation, and was authorized to operate in mainland China and Clinical trials, listing applications and commercialization in Hong Kong, Macau and Taiwan.
-
New news about essential medicines or increase in the proportion of essential medicines used
Time of Update: 2021-04-27
Medical Network News on March 23 Up-regulation ratio Recently, a circulating document shows that Jiangxi Province has recently adjusted the requirements for the proportion of essential medicines in public medical institutions.
-
Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseIn recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
-
More than 7,700 hospitals in my country have established an appointment diagnosis and treatment system
Time of Update: 2021-04-27
Medical Network News on March 24, National Health Commission’s Planning Development and Informatization Department Director Mao Qun’an said at a press conference of the National Health Commission on
-
Talking about: "Drug Patent Link System" of "Innovation & Imitation Communication Bridge"
Time of Update: 2021-04-24
Establishing a drug patent link system that suits national conditions usually has the following four important meanings: protecting the patent rights of original research drugs; encouraging generic drug patent challenges; establishing a standardized drug market access order to prevent malicious competition; and resolving patent disputes in established infringements.
-
Biogen's subcutaneous injection of natalizumab is approved in the EU for the treatment of multiple sclerosis
Time of Update: 2021-04-24
The new route of administration of the drug formulation provides comparable efficacy and safety to TYSABRI intravenous (IV) preparations, which are based on long-term treatment data, established clinical benefits and good safety.
-
Astellas geritinib fumarate tablets reach the primary endpoint of overall survival
Time of Update: 2021-04-24
Earlier this year, the China National Medical Products Administration (NMPA) conditionally approved geritinib for the treatment of FMS-like tyrosine kinase 3 (FLT3) mutations detected by fully validated detection methods Adult patients with relapsed or refractory acute myeloid leukemia (AML).
